Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Future Pharmtech Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This case is being handled by 1 distinct examiner and 1 distinct art unit. NESTOR, DONNA MICHELLE is the busiest examiner for the company, managing 1 pending office action.
The presence of only 1 pending office action across 1 distinct examiner and 1 distinct art unit reflects a very narrow and specific prosecution profile. The company's active patent interests in the pharmaceutical field are currently concentrated in this single matter. This lack of distribution means that the prosecution strategy is entirely focused on one examiner's perspective.
Practitioners should note that with 1 distinct examiner and 1 distinct art unit involved, there is no opportunity for examiner shopping or diversifying technical arguments across different groups. The success of the current portfolio rests on navigating the specific requirements of the assigned examiner. This concentrated focus simplifies the management of the portfolio but increases the importance of the single pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836532 | COMBINATION OF COMPOUNDS FOR TREATING VASCULAR DISEASES COMPRISING PDE5 INHIBITOR, ARGININE AND N-ACETYLCYSTEINE | NESTOR, DONNA MICHELLE | 1627 | §103§112 | Non-Final OA | — | Pending | Aug 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFuture Pharmtech Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Donna Michelle Nestor has the most, with 1 of Future Pharmtech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
